{
  "ticker": "AUK",
  "pdf_display_url": "https://www.asx.com.au/asx/v2/statistics/displayAnnouncement.do?display=pdf&idsId=02975382",
  "id": "02975382",
  "pages": 8,
  "price_sensitive": true,
  "date": "20250731",
  "time": "1528",
  "pdf_url": "https://announcements.asx.com.au/asxpdf/20250731/pdf/06md2jy533lhv2.pdf",
  "summary": "### **Quarterly Report (Appendix 4C) Summary:**  \n\n#### **Key Financial Highlights:**  \n- **Cash receipts:** $15.5m (+22% QoQ, +213% YoY)  \n- **Net cash used in operations:** $1.66m (vs. $288k in Q3 FY25) \u2013 due to advance product payments.  \n- **Operational cost reduction:** Underlying cash expenditure fell to $864k (from $1,142k in Q3 FY25).  \n- **Closing cash balance:** $1.677m (down from $3.381m last quarter).  \n- **Financing facility:** $1.0m debt drawn (total facility), no unused facilities available.  \n\n#### **Operational Highlights:**  \n- **Kabrita distribution agreement (April \u201925):** Exclusive 3-year deal for ANZ market; $1.5m+ in sales since signing.  \n- **Danone infant formula agreement (May \u201925):** $13m+ in sales via Rockcheck Shipping.  \n- **Business restructure (July \u201925):** Streamlined operations to focus on revenue growth and cost efficiency.  \n\n#### **Liquidity & Funding Risk:**  \n- **Funding runway:** ~1 quarter based on current cash burn.  \n- **Mitigation steps:** Cost-cutting (saving $400k/year in director fees), exploring capital raising options.  \n\n**Note:** No immediate liquidity crisis cited, but limited buffer (1 quarter) underscores need for revenue/cost execution.",
  "usage": {
    "prompt_tokens": 4416,
    "completion_tokens": 319,
    "total_tokens": 4735,
    "prompt_tokens_details": null
  },
  "model": "deepseek/deepseek-chat-v3-0324:free",
  "processed_at": "2025-07-31T06:01:28.112930"
}